---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000003"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:21:30.677117+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA

## Summary
- Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.
- Q4 2023 net revenues $133.8M, up 4% YoY; US contributed $91.3M, Germany $14.7M.
- 1,564 prescriptions in Q4 (+14% YoY); 3,755 active patients (+9% vs Q4 2022).
- PMA application for TTFields in NSCLC submitted to FDA/PMDA in December 2023.
- Appointed Dr. Nicolas Leupin as Chief Medical Officer effective Jan 1, 2024.

## SEC filing metadata
- accession: 0001645113-24-000003
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/nvcr-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000003
- JSON: https://secwatch.observer/filing/0001645113-24-000003.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000003.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported the quarter and year ended December 31, 2023 results: revenue $509.3 million.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $509.3 million
  - Result: preliminary results
  source text: --- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D. appointed as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.